🇺🇸 FDA

Intelligence · Clinical Pipeline

Theravance Biopharma Ireland Pipeline

All ClinicalTrials.gov programs at Theravance Biopharma Ireland — phase, modality, and trial IDs.

Programs
57

Quick answer

Theravance Biopharma Ireland has 57 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Revefenacin

    Theravance Biopharma Ireland Umited

    Chronic Obstructive Pulmonary Disease, COPD

    phase 3 small molecule completed

    2 trials

  2. TD-1473 Dose A

    Theravance Biopharma Ireland Umited

    Ulcerative Colitis (UC)

    phase 3 small molecule terminated

    2 trials

  3. TD-4208

    Theravance Biopharma Ireland Umited

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule completed

    4 trials

  4. ampreloxetine

    Theravance Biopharma Ireland Umited

    Symptomatic Neurogenic Orthostatic Hypotension

    phase 3 small molecule active

    4 trials

  5. 400 microgrammes GSK961081

    Theravance Biopharma Ireland Umited

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  6. Placebo

    Theravance Biopharma Ireland Umited

    Chronic Obstructive Pulmonary Disease, COPD

    phase 2 small molecule completed

    1 trial

  7. Placebo

    Theravance Biopharma Ireland Umited

    Crohn's Disease

    phase 2 small molecule terminated

    1 trial

  8. Revefenacin Inhalation Solution [Yupelri]

    Theravance Biopharma Ireland Umited

    COPD

    phase 2 small molecule completed

    1 trial

  9. TD-0903

    Theravance Biopharma Ireland Umited

    Acute Lung Injury (ALI) Associated With COVID-19

    phase 2 small molecule completed

    2 trials

  10. TD-1211

    Theravance Biopharma Ireland Umited

    Healthy

    phase 2 small molecule completed

    2 trials

  11. TD-1211

    Theravance Biopharma Ireland Umited

    Opioid Induced Constipation

    phase 2 small molecule completed

    2 trials

  12. TD-1211

    Theravance Biopharma Ireland Umited

    Opioid-induced Constipation (OIC)

    phase 2 small molecule completed

    1 trial

  13. TD-1792

    Theravance Biopharma Ireland Umited

    Staphylococcal Skin Infection

    phase 2 small molecule completed

    1 trial

  14. TD-4208

    Theravance Biopharma Ireland Umited

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  15. TD-4208

    Theravance Biopharma Ireland Umited

    COPD

    phase 2 small molecule completed

    2 trials

  16. TD-5108

    Theravance Biopharma Ireland Umited

    Chronic Constipation

    phase 2 small molecule completed

    1 trial

  17. TD-8236

    Theravance Biopharma Ireland Umited

    Asthma

    phase 2 small molecule completed

    2 trials

  18. TD-9855

    Theravance Biopharma Ireland Umited

    Neurogenic Orthostatic Hypotension

    phase 2 small molecule completed

    1 trial

  19. TD-9855

    Theravance Biopharma Ireland Umited

    Attention-Deficit/Hyperactivity Disorder

    phase 2 small molecule completed

    1 trial

  20. TD-9855 Group 1

    Theravance Biopharma Ireland Umited

    Fibromyalgia

    phase 2 small molecule completed

    1 trial

  21. Telavancin

    Theravance Biopharma Ireland Umited

    Infection

    phase 2 small molecule completed

    1 trial

  22. Velusetrag

    Theravance Biopharma Ireland Umited

    Gastroparesis

    phase 2 small molecule completed

    1 trial

  23. velusetrag dose 1

    Theravance Biopharma Ireland Umited

    Gastroparesis

    phase 2 small molecule completed

    1 trial

  24. Ampreloxetine

    Theravance Biopharma Ireland Umited

    Symptomatic Neurogenic Orthostatic Hypertension

    phase 1 small molecule completed

    1 trial

  25. Ampreloxetine <Dose A>

    Theravance Biopharma Ireland Umited

    Symptomatic Neurogenic Orthostatic Hypertension

    phase 1 small molecule completed

    1 trial

  26. GSK961081

    Theravance Biopharma Ireland Umited

    Pulmonary Disease, Chronic Obstructive

    phase 1 small molecule completed

    2 trials

  27. GSK961081 15mcg SD

    Theravance Biopharma Ireland Umited

    Pulmonary Disease, Chronic Obstructive

    phase 1 small molecule completed

    1 trial

  28. Nezulcitinib (TD-0903) Dose A

    Theravance Biopharma Ireland Umited

    Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)

    phase 1 small molecule completed

    1 trial

  29. TD-0714

    Theravance Biopharma Ireland Umited

    Healthy Adults, Elderly Subjects

    phase 1 small molecule completed

    1 trial

  30. TD-0714

    Theravance Biopharma Ireland Umited

    Healthy

    phase 1 small molecule completed

    1 trial

  31. TD-1058

    Theravance Biopharma Ireland Umited

    Idiopathic Pulmonary Fibrosis (IPF)

    phase 1 small molecule terminated

    1 trial

  32. TD-1211 Dose 1

    Theravance Biopharma Ireland Umited

    Constipation

    phase 1 small molecule completed

    1 trial

  33. TD-1439

    Theravance Biopharma Ireland Umited

    Healthy Subjects

    phase 1 small molecule completed

    1 trial

  34. TD-1439

    Theravance Biopharma Ireland Umited

    Healthy Adults, Elderly Subjects

    phase 1 small molecule completed

    1 trial

  35. TD-1473

    Theravance Biopharma Ireland Umited

    Ulcerative Colitis, Active Moderate

    phase 1 small molecule completed

    1 trial

  36. TD-1473

    Theravance Biopharma Ireland Umited

    Inflammatory Bowel Disease

    phase 1 small molecule completed

    1 trial

  37. TD-1473 - Dose A

    Theravance Biopharma Ireland Umited

    Inflammatory Bowel Diseases

    phase 1 small molecule completed

    1 trial

  38. TD-1473 [Tablet A]

    Theravance Biopharma Ireland Umited

    Intestinal Disorder

    phase 1 small molecule completed

    1 trial

  39. TD-1473 for SAD

    Theravance Biopharma Ireland Umited

    Healthy

    phase 1 small molecule completed

    1 trial

  40. TD-1473 oral capsule

    Theravance Biopharma Ireland Umited

    Intestinal Disorders

    phase 1 small molecule completed

    1 trial

  41. TD-1607

    Theravance Biopharma Ireland Umited

    Infections

    phase 1 small molecule completed

    1 trial

  42. TD-1607

    Theravance Biopharma Ireland Umited

    Serious Infections Due to Known or Suspected Gram-positive Pathogens

    phase 1 small molecule completed

    1 trial

  43. TD-3504

    Theravance Biopharma Ireland Umited

    Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects

    phase 1 small molecule completed

    1 trial

  44. TD-4208

    Theravance Biopharma Ireland Umited

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  45. TD-4208

    Theravance Biopharma Ireland Umited

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  46. TD-4208 175 mcg

    Theravance Biopharma Ireland Umited

    Cardiac Repolarization in Healthy Subjects

    phase 1 small molecule completed

    1 trial

  47. TD-5202

    Theravance Biopharma Ireland Umited

    Healthy

    phase 1 small molecule completed

    1 trial

  48. TD-6450

    Theravance Biopharma Ireland Umited

    Hepatitis C

    phase 1 small molecule completed

    2 trials

Frequently asked questions

How many pipeline programs does Theravance Biopharma Ireland have?

57 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.